Tessa Romero
Stock Analyst at JP Morgan
(3.67)
# 948
Out of 4,413 analysts
36
Total ratings
43.33%
Success rate
10.42%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $29 → $25 | $17.05 | +46.63% | 4 | Mar 25, 2024 | |
| NMRA Neumora Therapeutics | Maintains: Overweight | $20 → $22 | $9.10 | +141.76% | 3 | Mar 18, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $78 → $77 | $63.37 | +21.51% | 2 | Mar 7, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $31 → $30 | $33.66 | -10.87% | 3 | Feb 23, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | $32 → $56 | $40.18 | +39.37% | 4 | Feb 23, 2024 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $35 | $18.04 | +94.01% | 1 | Jan 22, 2024 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $20 | $12.30 | +62.60% | 1 | Nov 28, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $8 → $7 | $16.49 | -57.55% | 5 | Aug 22, 2023 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $20 → $22 | $25.83 | -14.83% | 2 | Aug 9, 2023 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $24 → $25 | $19.01 | +31.51% | 6 | Jun 30, 2023 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $54 → $55 | $42.49 | +29.44% | 2 | Apr 25, 2023 | |
| MCRB Seres Therapeutics | Initiates: Neutral | $7 | $1.08 | +548.15% | 1 | Apr 21, 2023 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $38 → $20 | $14.96 | +33.69% | 2 | Nov 18, 2022 |
ACADIA Pharmaceuticals
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $17.05
Upside: +46.63%
Neumora Therapeutics
Mar 18, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $9.10
Upside: +141.76%
Cytokinetics
Mar 7, 2024
Maintains: Overweight
Price Target: $78 → $77
Current: $63.37
Upside: +21.51%
Agios Pharmaceuticals
Feb 23, 2024
Maintains: Neutral
Price Target: $31 → $30
Current: $33.66
Upside: -10.87%
Biohaven Pharmaceutical Holding Company
Feb 23, 2024
Maintains: Overweight
Price Target: $32 → $56
Current: $40.18
Upside: +39.37%
EyePoint Pharmaceuticals
Jan 22, 2024
Initiates: Overweight
Price Target: $35
Current: $18.04
Upside: +94.01%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $12.30
Upside: +62.60%
Y-mAbs Therapeutics
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $16.49
Upside: -57.55%
Dyne Therapeutics
Aug 9, 2023
Maintains: Overweight
Price Target: $20 → $22
Current: $25.83
Upside: -14.83%
Edgewise Therapeutics
Jun 30, 2023
Maintains: Overweight
Price Target: $24 → $25
Current: $19.01
Upside: +31.51%
Xenon Pharmaceuticals
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $42.49
Upside: +29.44%
Seres Therapeutics
Apr 21, 2023
Initiates: Neutral
Price Target: $7
Current: $1.08
Upside: +548.15%
Scholar Rock Holding
Nov 18, 2022
Maintains: Overweight
Price Target: $38 → $20
Current: $14.96
Upside: +33.69%